Nikolai Podoltsev

Associate Professor at Biochemistry, Yale University9 Followers

Professor innovating in the area of hematology, Dr. Nikolai Podoltsev is an esteemed Associate Professor of Medicine at Yale University School of Medicine. With a specialized focus on hematological disorders, Dr. Podoltsev has dedicated his career to the treatment and research of conditions such as leukemia, myeloproliferative neoplasms, aplastic anemia, and bone marrow failure syndromes. His expertise in these areas has made him a sought-after clinician and researcher, contributing significantly to advancements in hematology. Dr. Podoltsev's role extends beyond patient care; he is deeply involved in clinical research, serving as the Principal Investigator for several clinical trials. His research endeavors aim to improve therapeutic strategies and outcomes for patients suffering from complex hematological conditions. His work in this field is characterized by a commitment to translating research findings into practical treatments that can be applied in clinical settings. In addition to his clinical and research responsibilities, Dr. Podoltsev is a dedicated educator. As the Associate Director of the Yale Hematology/Oncology Fellowship Program, he plays a pivotal role in shaping the next generation of hematologists. His educational contributions are further highlighted by his position as the Duffy Firm Chief for Education at Yale-New Haven Hospital, where he oversees educational initiatives and mentors medical trainees. Dr. Podoltsev's dedication to education has been recognized through numerous awards, reflecting his impact on medical training and mentorship. His approach to teaching is characterized by a blend of rigorous academic standards and compassionate guidance, fostering an environment where students and fellows can thrive. Through his multifaceted career, Dr. Podoltsev continues to influence the fields of hematology and medical education, driving innovation and excellence. His work not only enhances patient care but also inspires future leaders in medicine, ensuring that his contributions will resonate for years to come.

Research Interests

Leukemia Myeloproliferative neoplasms Aplastic anemia Bone marrow failure syndromes Hematological disorders Clinical trials Hematology education Therapeutic strategies

Publications

1 - Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States,Blood

Rory M. Shallis , Rong Wang , Jan Philipp Bewersdorf , Amer M. Zeidan , Scott F. Huntington , Amy J Davidoff , Xiaomei Ma , Nikolai A. Podoltsev ,

, 44-45, 2020-11-05

2 - Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States,Blood

Rong Wang , Rory M. Shallis , Jan Philipp Bewersdorf , Amer M. Zeidan , Scott F. Huntington , Xiaomei Ma , Nikolai A. Podoltsev ,

, 13-14, 2020-11-05

3 - Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US),Blood

Xiaoyi Wang , Rong Wang , Chi Zhang , Amer M. Zeidan , Nikolai A. Podoltsev , Scott F. Huntington , Steven D. Gore , Amy J Davidoff , Xiaomei Ma ,

, 4748-4748, 2019-11-13

4 - Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States,Blood

Rory M. Shallis , Rong Wang , Amer M. Zeidan , Scott F. Huntington , Natalia Neparidze , Mengyang Di , Xiaomei Ma , Nikolai Podoltsev ,

, 282-282, 2021-11-05

5 - The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia,Blood

Nikolai A. Podoltsev , Rong Wang , Rory M Shallis , Scott F. Huntington , Amer M. Zeidan , Steven D. Gore , Amy J Davidoff , Xiaomei Ma ,

, 2125-2125, 2019-11-13

6 - Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea,Blood

Rong Wang , Rory M Shallis , Scott F. Huntington , Amer M. Zeidan , Steven D. Gore , Amy J Davidoff , Xiaomei Ma , Nikolai A. Podoltsev ,

, 330-330, 2019-11-13

7 - Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting,Blood

Jan Philipp Bewersdorf , Wei Wei , Anna Jaiani , Prital Patel , Rajni Mehta , Natalia Neparidze , Rory M. Shallis , Nikolai Podoltsev , Andrew M. Brunner , Amer M. Zeidan ,

, 3701-3701, 2021-11-05

8 - Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis,Blood

Mengyang Di , Can Cui , Shalin K. Kothari , Amer M. Zeidan , Nikolai Podoltsev , Natalia Neparidze , Rory M. Shallis , Rong Wang , Xiaomei Ma , Scott F. Huntington ,

, 182-182, 2021-11-05

9 - Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia,Blood

Rory M. Shallis , Nikolai A. Podoltsev , Thomas Prebet , Amer M. Zeidan ,

, 29-29, 2020-11-05

10 - Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period,Blood

Natalia Neparidze , Rong Wang , Amer M. Zeidan , Nikolai Podoltsev , Rory M. Shallis , Xiaomei Ma , Amy J. Davidoff , Scott F. Huntington ,

, 4092-4092, 2021-11-05

11 - Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia,Blood

Jan Philipp Bewersdorf , George Goshua , Kishan K Patel , Rory M. Shallis , Nikolai Podoltsev , Scott F. Huntington , Amer M. Zeidan ,

, 113-113, 2021-11-05

12 - Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis,Blood

Naveen Pemmaraju , Krishna Gundabolu , Kristen Pettit , Moshe Talpaz , Nikolai A. Podoltsev , Gary J. Schiller , Peter Eisenberg , Hagop Youssoufian , Susan Duggan , Barbara Wallner , Srdan Verstovsek ,

, 4178-4178, 2019-11-13

13 - Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study,Blood

Shelby Meckstroth , Rong Wang , Xiaomei Ma , Nikolai A. Podoltsev ,

, 21-22, 2020-11-05

14 - Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study,Blood

Nikolai Podoltsev , Mengxin Zhu , Rong Wang , Amer M. Zeidan , Xiaoyi Wang , Amy J. Davidoff , Scott F Huntington , Smith Giri , Steven D. Gore , Xiaomei Ma ,

, 3580-3580, 2018-11-29

15 - Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study,Blood

Nikolai Podoltsev , Mengxin Zhu , Rong Wang , Amer M. Zeidan , Xiaoyi Wang , Scott F Huntington , Smith Giri , Amy J. Davidoff , Steven D. Gore , Xiaomei Ma ,

, 4865-4865, 2018-11-29

16 - Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions,Blood

Amer M. Zeidan , Weiwei Zhu , Rong Wang , Maximilian Stahl , Scott F Huntington , Smith Giri , Nikolai A. Podoltsev , Steven D. Gore , Xiaomei Ma , Amy J. Davidoff ,

, 838-838, 2018-11-29

Share Nikolai's Profile